Sickle Cell Treatment Demonstration Program

The summary for the Sickle Cell Treatment Demonstration Program grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Health Resources and Services Administration, which is the U.S. government agency offering this grant.

Sickle Cell Treatment Demonstration Program: The purpose of this grant activity is to support the Sickle Cell Treatment Demonstration Program authorized in Public Law 108-357, Section 712(c). Its purpose is to develop and establish systemic mechanisms to enhance the prevention and treatment of sickle cell disease through the coordination of service delivery; genetic counseling and testing; bundling of technical services; training of health professionals; and other related efforts. Up to four (4) regional Sickle Cell Disease Collaborative Networks (Networks) will be funded for a period of four (4) years, subjected to availability of funding, satisfactory grantee performance, and a determination that continued funding is in the best interest of the government. No more than two (2) applicants will be funded from any one of the previously defined HRSA Regional Genetic and Newborn Screening Collaborative regions.